Additionally, Nørgaard et al. (2022) have offered compelling evidence indicating that GLP-1 treatment in patients with type 2 diabetes could potentially open a new avenue for reducing the occurrence of dementia [163]. Here, GCG is linked to type 2 diabetes mellitus.